Tag: FOR

New versatile business laptop line adds 360° convertible for enterprise and education

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock on the New York Stock Exchange (“NYSE”) of Stellantis N.V. (NYSE: STLA) between February 26, 2025 and February 5, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

New York, June 01, 2026 (GLOBE NEWSWIRE) -- Tribeca Strategic Acquisition Corp. (the “Company”), announced today the closing of its initial public offering of 14,000,000 units at a price of $10.00 per unit, which resulted in gross proceeds of $140,000,000. The units are listed on the Nasdaq Global Market (“Nasdaq”) and began trading on May 29, 2026, under the ticker symbol “BIDWU.” Each unit consists of one Class A ordinary share and one right (the “Share Right”) to receive one tenth (1/10) of one Class A ordinary share upon the consummation of an initial business combination.  There are no warrants issued publicly or privately in connection with this offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and Share Rights are expected to be listed on Nasdaq under the symbols “BID” and “BIDWR,” respectively.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026.

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.